Протокол ведения больных РС 49 — Рассеянный склероз: энциклопедия

Протокол ведения больных РС 49


Приложение 5

к Протоколу ведения больных

«Рассеянный склероз»

БИБЛИОГРАФИЯ

  1. Доказательная медицина: ежегодный справочник. Вып. 2, ч. 2. – М.: Медиа Сфера, 2003. — С. 748-850.
  2. Achiron A., Miron S. Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis // Multiple sclerosis clinical and laboratory research. — 2000. — Vol. 6. — Suppl. 2. — 6-9.
  3. Barnes M.P., Gilhus N.E., Wender M. Task force on minimum standards for health care of people with multiple sclerosis // Europ. J. Neurol. – 2001 – Vol. 8. – P. 215-220.
  4. Bashir K., Whitaker S.N. Handbook of multiple sclerosis. — Lippincott Williams & Wilkins, 2001. — 248 p.
  5. Bornstein M.B., Miller A., Slagle S. et al. A pilot tzial of Cop 1 in exacerbating-remitting multiple sclerosis // New Eng. J. Med. – 1987. – Vol. 317. – P. 408-414.
  6. Bose , Ladkani D., Burell A., Sharief M. Cost-effectiveness analysis of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis // J. Med. Econom. – 2001. — Vol. 4. — P. 207-219.
  7. Clanet M., Radue E.W., Kappos L. et al. The European IFNβ-1a (Avonex) Dose-Comparison Study Group. A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS // Neurology. – 2002. — Vol. 59. – P. 1507-1517.
  8. Clegg A., Bryant J. Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness // Expert Opin.Pharmacother. – 2001. — Vol. 2. — P. 623-639.
  9. Compston A. Treatment and management of multiple sclerosis // In: McAlpine’s Multiple Sclerosis, 1999. – P. 437-498.
  10. Comi G., Filippi M., Wolinsky J.S. The European/Canadian Glatiramer Acetate Study Group. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis // Ann. Neurol. — 2001. — Vol. 49. — P. 290-297.
  11. Coyle P.K., Hartung H.-P. Use of interferon beta in multiple sclerosis: rational for early treatment and evidence for dose- and frequency-dependent effects on clinical response // Multiple Sclerosis. – 2002. — Vol. 8. – P. 2-9.
  12. Durelli L. Dose and frequency of interferon treatment matter INCOMIN and OPTIMS // J. Neurol. – 2003. — Vol. 250. — Suppl. 4. — P. 9-14.
  13. Goodin D.S., Frohman E.M., Garmany G.P. et al. Disease modifying therapies in multiple sclerosis // Neurology. – 2002. — Vol. 58. — P. 169-178.
  14. Haas J. High dose IvIgG in the post partum period for prevention of exacerbations in MS // Multiple sclerosis: clinical and laboratory research. – 2000. — Vol. 6. – Suppl. 2. – P. 18-20.
  15. Johnson K.P., Brooks B.R., Ford C.C. et al. The Copolymer 1 Multiple sclerosis Study Group. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years // Multiple Sclerosis. – 2000. — Vol. 6. — P. 255-266.
  16. Khan O.A., Tselis A.C., Kamholz J.A. et al. A prospective, open-label treatment trial to compare the effect of IFN β-1 a (Avonex®), IFN β-1bb(Betaseron®), and glatiramer acetate (Copaxone®) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy // Ibid. – 2001. – Vol. 7. – P. 349-353.
  17. Khan O., Zabad R., Caon Ch. et al. Comparative Assessment of immunomodulating therapies for relapsing-remitting multiple sclerosis // CNS Drugs. – 2002. – Vol. 16. – P. 563-578.
  18. Kobelt G. Economic considerations and outcome measurement in urine incontinence // Urology. – 1997. — Vol. 50. – Suppl. 6A. – P. 100-107.
  19. Kobelt G., Jonsson L., Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov Model // Neurourology and Urodynamics.– 1998. — Vol. 17. — P. 599-611.
  20. Kobelt G., Jonsson L., Miltenburger C., Jonsson B. Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis using natural history disease data // Int. J. Technol. – 2002. — Vol. 18 (1). — P. 127-138.
  21. LublinD., Reingold S.C. The National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis // Neurology. – 1997. — Vol. 48. — P. 572-574.
  22. Mancardi G.L., Sardanelli F., Parodi R.C. et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis. // Ibid. – 1998. — Vol. 50. – P. 1127-1133.
  23. McDonald W.I., Compston A., Edan G. et al. Recommended diagnostic Criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis // Annals of Neurology. — 2001 – Vol. 50, No. 1. – P. 121-127.
  24. Molyneux P.D., Kappos L., Polman C. et al. The European Study Group on interferon beta-1b in secondary progressive multiple sclerosis. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis // Brain. – 2000. — Vol. 123. — P. 2256-2263.
  25. O’Connor P. Key issues in the diagnosis and treatment of multiple sclerosis: and overview // Neurology. – 2002. — Vol. 59. – Suppl. 3. — P. 1-31.
  26. Sela M., Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis // Expert Opin. Pharmacother. – 2001 – Vol. 2. — P. 1149-1165.
  27. Strasser-Fuchs S., Fazekas F., Deisenhammer F. et al. The Austrian Immunoglobulin in MS (AIMS) study: final analysis // Multiple sclerosis: clinical and laboratory research. – 2000. — Vol. 6. – Suppl. 2. – P. 9-12.
  28. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis // Neurology. – 1993. – Vol. 43. — P. 655-661.
  29. Weinshenker B.G. Plasma exchange for acute attacks of demyelinating diseases // Therapeutic Apheresis. – 2000. – Vol. 4. – P. 187-189.

<< назад

содержание